Quick answer: Zepbound is Eli Lilly's tirzepatide, a once-weekly shot approved for weight loss and for obstructive sleep apnea with obesity. Ozempic is Novo Nordisk's semaglutide, a once-weekly shot approved for type 2 diabetes; it has no weight-loss approval. Nobody has run a trial of Zepbound against Ozempic as labelled. The nearest evidence: tirzepatide given as Mounjaro took off 11.2 kg against 5.7 kg for Ozempic 1 mg in people with diabetes (SURPASS-2), and Zepbound averaged 20.2% against 13.7% for semaglutide at the Wegovy dose in people without it (SURMOUNT-5). Cash prices: Zepbound vials and KwikPens $299–$449 a month from LillyDirect; Ozempic $349 a month through the 1 mg dose and $499 for 2 mg, from NovoCare.
Zepbound and Ozempic are both weekly GLP-1-based injections, but they are different molecules from different makers, with different FDA labels. Zepbound is tirzepatide, which acts on GIP and GLP-1 receptors and is approved for weight; Ozempic is semaglutide, which acts on GLP-1 receptors and is approved for type 2 diabetes. Most people searching this pair want to know which does more for weight. The fair brand-to-brand answer is Zepbound vs Wegovy (both labelled for weight) or Mounjaro vs Ozempic (both labelled for diabetes); this page explains what the evidence says about the cross-brand pair and what each costs.
- Two jobs: Zepbound treats obesity and obesity-related sleep apnea; Ozempic treats type 2 diabetes and protects the heart and kidneys in it. Ozempic is not approved for weight loss.
- Tirzepatide out-lost semaglutide in both head-to-head trials, though neither tested these two brands: SURPASS-2 pitted Mounjaro against Ozempic 1 mg; SURMOUNT-5 pitted Zepbound against Wegovy's dose.
- A year of self-pay medicine, by our arithmetic: roughly $5,188 for Zepbound vials or KwikPens and $3,888 for Ozempic held at 1 mg or less.
At a glance
| Zepboundtirzepatide · Lilly | Ozempicsemaglutide · Novo | |
|---|---|---|
| FDA-approved for | Weight reduction and long-term maintenance in adults with obesity, or overweight plus a weight-related condition; moderate-to-severe obstructive sleep apnea in adults with obesity (Dec 2024) | Type 2 diabetes: lowering A1C, and cutting cardiac and kidney risks for people who have the disease (label); no weight-management approval |
| Not labelled for | Type 2 diabetes (that tirzepatide label is Mounjaro) | Weight management (that semaglutide label is Wegovy) |
| Forms | Single-dose pen; KwikPen (4 weekly doses); single-dose and multi-dose vials, sold only through LillyDirect | A month-long pen holding four weekly doses; also a daily tablet |
| Dose steps | Start on 2.5 mg; add 2.5 mg no sooner than every 4 weeks; stay on 5, 10 or 15 mg | 0.25 mg, then 0.5 mg, each for a month; 1 and 2 mg added if glucose stays high |
| Maximum dose | 15 mg weekly | 2 mg weekly |
| Self-pay from | $299 a month (2.5 mg vial or KwikPen) | $199 a pen for a new patient's first two, then $349 |
What the research shows
No trial has given people Zepbound or Ozempic as labelled. Two head-to-head trials compared their molecules, each under another brand's label and dose, so read every row with its population in mind.
| Result | Zepboundtirzepatide · Lilly | Ozempicsemaglutide · Novo |
|---|---|---|
| Kilograms lost in 40 weeks, people with type 2 diabetesCounting: treatment-regimen: anyone dosed, even if they later stopped | 11.2 kgSURPASS-2 (tirzepatide as Mounjaro), 1,879 people, 40 weeks; 15 mg | 5.7 kgSURPASS-2 (tirzepatide as Mounjaro), 1,879 people, 40 weeks; Ozempic at 1 mg |
| Percent of body weight lost in 72 weeks, obesity without diabetesCounting: treatment-regimen: anyone randomized, even if they later stopped | 20.2%SURMOUNT-5, 751 people, 72 weeks; Zepbound 10 or 15 mg | 13.7%SURMOUNT-5, 751 people, 72 weeks; semaglutide 1.7 or 2.4 mg, given as Wegovy, not Ozempic |
SURPASS-2 enrolled 1,879 adults with type 2 diabetes for 40 weeks; SURMOUNT-5 enrolled 751 adults with obesity and no diabetes for 72. Lilly paid for both, and neither was blinded. Diabetes tends to blunt weight loss on these drugs, one reason the two rows look so different. Compounded versions borrow none of these results.
Two different molecules
Tirzepatide mimics two gut hormones, GIP and GLP-1; semaglutide mimics GLP-1 alone. Both slow stomach emptying and reduce appetite, and both are dosed once a week, but they are not interchangeable and their milligram doses mean different things (15 mg of tirzepatide is not "more" than 2 mg of semaglutide). Each molecule is sold under two labels: tirzepatide as Zepbound (weight) and Mounjaro (diabetes), semaglutide as Wegovy (weight) and Ozempic (diabetes). Molecule-level detail: Tirzepatide vs Semaglutide: molecule-level comparison and the 2026 head-to-head update; the two semaglutide labels: Ozempic vs Wegovy — what's the actual difference? (doses and prices).
Can Ozempic be used for weight loss?
Ozempic's label is a diabetes label. Doctors may legally prescribe it off-label for weight, but that is their judgment, and most insurers pay for Ozempic only alongside a type 2 diabetes diagnosis, so off-label use usually means paying cash. The semaglutide product dosed and approved for weight is Wegovy, which in its own trial of people without diabetes averaged 14.9% at 2.4 mg (STEP 1); in Zepbound's own trial, 15 mg averaged 20.9% (SURMOUNT-1). Separate trials, so not a head-to-head. Zepbound's label applies to adults who meet the BMI criteria: a BMI of 30 or more, or 27 or more with a weight-related condition (see also the NIDDK guide to prescription weight-loss drugs). Across every option: Which GLP-1 is most effective for weight loss?
Who should consider each drug?
| If you… | What the labels and trials point to |
|---|---|
| Want a medicine approved for weight loss | Zepbound (or Wegovy); Ozempic is not labelled for weight |
| Need A1C brought down | Ozempic is approved for it; Zepbound is not, though its molecule is (as Mounjaro) |
| Have sleep apnea with obesity | Zepbound holds that approval |
| Have diabetes-related kidney disease | Ozempic, which has a kidney-outcome approval |
| Have diabetes and a past heart attack or stroke | Ozempic has the heart-risk approval; for tirzepatide that approval sits with Mounjaro, not Zepbound |
| Use birth-control pills | For 4 weeks after starting Zepbound and after each step up, its label advises a non-oral or added barrier method; nothing like that appears in Ozempic's label |
| Need insurance to pay | Plans usually cover Ozempic only for type 2 diabetes; coverage of Zepbound for weight varies widely by plan |
Diagnosis, other medicines and coverage all feed the prescriber's choice.
Side-effect profiles
The side-effect profiles overlap significantly: nausea, vomiting, diarrhea, constipation, mostly in the weeks after a dose increase. Each label reports them from its own placebo-controlled trials, so the columns below describe different people at different doses:
| Side effect | Zepboundtirzepatide · Lilly | Ozempicsemaglutide · Novo |
|---|---|---|
| Nausea | 28% (8%) | 20.3% (6.1%) |
| Diarrhea | 23% (8%) | 8.8% (1.9%) |
| Vomiting | 13% (2%) | 9.2% (2.3%) |
| Constipation | 11% (5%) | 3.1% (1.5%) |
| Injection-site reactions | 8% (2%) | Not among the label's common reactions |
When both molecules ran in one trial of people with type 2 diabetes (SURPASS-2), stomach complaints came out similar: nausea in 17–22% on tirzepatide and 18% on semaglutide 1 mg. Each label's boxed warning concerns thyroid C-cell tumors seen in rodents, and neither drug is for someone with medullary thyroid cancer, or a relative with it, or MEN 2. Other label warnings in common: pancreatitis, gallbladder disease, kidney injury when dehydrated, low blood sugar with insulin or sulfonylureas, and inhaling stomach contents under anesthesia. The 2025 FDA PDFs: Ozempic; tirzepatide (Mounjaro NDA). Compare more: Which GLP-1 has the fewest side effects?
Cost and access in 2026
Both are sold self-pay by their makers. Zepbound's price climbs with each dose step, while Ozempic holds one price through 1 mg before a higher 2 mg tier:
| Option | Month 1 | Usual maintenance month | First-year estimate | Source |
|---|---|---|---|---|
| Zepbound vial or KwikPen (LillyDirect) | $299 (2.5 mg) | $399 at 5 mg; $449 at 7.5–15 mg if refilled within 45 days ($499–$699 if later) | $5,188 | LillyDirect Zepbound |
| Ozempic, staying at or below 1 mg | $199 (first-two-pens offer) | $349 | $3,888 | NovoCare |
| Ozempic, titrated to 2 mg | $199 (first-two-pens offer) | $499 | $5,238 | NovoCare |
Year-one totals are our arithmetic on list cash prices, medicine only, twelve monthly fills. Zepbound path: 2.5 mg, 5 mg, then ten months at 7.5 mg or more, each refilled inside 45 days. Ozempic held at 1 mg: two offer pens, ten at $349. Ozempic stepped to 2 mg: two offer pens, a 1 mg month, nine at $499. Since each fill is four weeks, a calendar year actually needs thirteen. The Ozempic offer ends Dec 31, 2026.
Lilly sells Zepbound vials and KwikPens self-pay through LillyDirect; the single-dose pen is the format most insurers cover. When commercial insurance covers the drug, Lilly's and Novo's savings cards can cut a fill to "as little as $25", within monthly caps (Zepbound terms, Ozempic terms), and neither works with Medicare or Medicaid. Medicare's GLP-1 Bridge covers the Zepbound KwikPen for weight at $50 a month for eligible Part D members through 2027; Ozempic is covered under Part D for type 2 diabetes, depending on the plan. For anyone who finds the out-of-pocket cost a real barrier, see what Ozempic costs without insurance, Zepbound cost without insurance, the GLP-1 cost guide (2026), or compare published GLP-1 prices.
Can you switch from Ozempic to Zepbound?
Switching from a semaglutide product such as Ozempic to Zepbound takes a new prescription, and Zepbound's label starts at 2.5 mg for 4 weeks whatever semaglutide dose came before; there is no dose-equivalence table between them. For someone with type 2 diabetes, the prescriber also plans blood-sugar control through the change, since Zepbound's label is for weight and doses of insulin or sulfonylureas may need adjusting. Insurance treats the two under different benefits, so coverage can change with the switch.
Compounded tirzepatide and semaglutide: where they fit
Telehealth sellers also offer compounded semaglutide and compounded tirzepatide, prepared by state-licensed pharmacies. Both are not FDA-approved, nor FDA-reviewed for safety, effectiveness or quality, and neither is the same product as Zepbound or Ozempic, so the SURPASS and SURMOUNT figures here tell you nothing about them. The FDA page on human drug compounding has the regulator's view. Further reading: Brand-name vs compounded GLP-1 cost comparison, Compounded tirzepatide vs Zepbound, Compounded semaglutide vs Wegovy. Dated prices, brand and compounded: semaglutide cost without insurance and our GLP-1 price comparison.
Related comparisons
- Zepbound vs Wegovy (both approved for weight)
- Foundayo vs Zepbound (pill vs shot)
- Ozempic vs Wegovy — both semaglutide, different doses
- Tirzepatide vs Semaglutide — the molecules compared
- Brand-name vs compounded GLP-1 — cost, access, and key differences
Frequently asked questions
Is Zepbound the same as Ozempic?
No: Zepbound is Lilly's tirzepatide, approved for weight reduction and obstructive sleep apnea, and Ozempic is Novo Nordisk's semaglutide, approved for type 2 diabetes. They are different molecules from different makers.
Which is better for weight loss, Zepbound or Ozempic?
Zepbound is the one FDA-approved for weight loss, and tirzepatide beat semaglutide on weight in both head-to-head trials, SURPASS-2 and SURMOUNT-5. Neither trial tested Zepbound against Ozempic as labelled, and individual results vary.
Can I use Ozempic for weight loss?
Ozempic's approval is for type 2 diabetes, not weight management; some prescribers use it off-label, and insurers often limit coverage to diabetes. The semaglutide product approved for weight is Wegovy.
Is Zepbound stronger than Ozempic for weight loss?
On average tirzepatide lowered weight more: 20.2% versus 13.7% against semaglutide at Wegovy's dose in SURMOUNT-5, and 11.2 kg versus 5.7 kg against Ozempic 1 mg in SURPASS-2. These are trial averages, not predictions for one person.
Can I switch from Ozempic to Zepbound?
Yes, under a prescriber's care: Zepbound starts at its 2.5 mg dose for 4 weeks whatever Ozempic dose came before, because there is no milligram conversion. People with type 2 diabetes also need a plan for blood-sugar control during the change.
Do Zepbound and Ozempic have the same side effects?
Mostly the same kind: nausea, diarrhea, vomiting and constipation, worst after dose increases, plus the same boxed thyroid warning. In SURPASS-2, stomach side-effect rates were similar on tirzepatide and on semaglutide 1 mg.
Which costs less without insurance, Zepbound or Ozempic?
Self-pay, Zepbound vials and KwikPens run $299 to $449 a month through LillyDirect and NovoCare charges $349 for Ozempic through 1 mg and $499 for 2 mg (checked Oct 13, 2026). By our arithmetic, a first year comes to about $5,188 on Zepbound and $3,888 on Ozempic up to 1 mg.
Is Zepbound approved for type 2 diabetes?
No, Zepbound is approved for weight reduction and obstructive sleep apnea; the same molecule is sold for type 2 diabetes as Mounjaro.
Sources and references
- SURPASS-2: tirzepatide versus semaglutide once weekly in type 2 diabetes (Frías et al., New England Journal of Medicine, 2021) (accessed Oct 13, 2026)
- SURMOUNT-5: tirzepatide compared with semaglutide for obesity (Aronne et al., New England Journal of Medicine, 2025) (accessed Oct 13, 2026)
- SURMOUNT-1: once-weekly tirzepatide for obesity (Jastreboff et al., New England Journal of Medicine, 2022) (accessed Oct 13, 2026)
- STEP 1: once-weekly semaglutide in overweight or obesity (Wilding et al., New England Journal of Medicine, 2021) (accessed Oct 13, 2026)
- Zepbound label on DailyMed, September 2026 (accessed Oct 13, 2026)
- Ozempic label on DailyMed, June 2026 (accessed Oct 13, 2026)
- Mounjaro label on DailyMed, August 2026 (SURPASS-2 weight table) (accessed Oct 13, 2026)
- FDA release on Zepbound for obstructive sleep apnea, December 20, 2024 (accessed Oct 13, 2026)
- LillyDirect Zepbound pricing (accessed Oct 13, 2026)
- Zepbound coverage and savings terms (accessed Oct 13, 2026)
- Ozempic price guide from NovoCare (accessed Oct 13, 2026)
- Ozempic savings offer from NovoCare (accessed Oct 13, 2026)
- Medicare GLP-1 Bridge program page (CMS) (accessed Oct 13, 2026)
This page compares published trials, FDA labels and makers' price pages; it is not medical advice, and a licensed prescriber decides which drug and dose fit you. Trial results are for the FDA-approved branded drugs only. Nouri is a publisher; it does not prescribe or sell any medication, and it is not affiliated with Eli Lilly or Novo Nordisk. Facts checked Oct 13, 2026; prices change, so confirm at the source.
Disclosure: Nouri may earn a commission when you sign up with some of the providers we link to. It doesn't change what you pay or how we rank providers. This comparison has no partner link in its text, and no drug maker paid for it. Full disclosure.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Nouri is an independent publisher: it does not prescribe, review patient assessments, or sell medication. Talk to a licensed clinician before starting or changing any medication or treatment.
Compare licensed GLP-1 providers
Published cash prices side by side, with the month we checked them and a link to each provider's own site. Nouri doesn't prescribe or sell medication.